Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986218

Next Previous
Search
Drug Profile

BMS 986218

Alternative Names: Anti-CTLA-4 NF - Bristol-Myers Squibb; BMS-986218

Latest Information Update: 17 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Columbia University; Ferring Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer; Solid tumours

Most Recent Events

  • 08 Sep 2024 Efficacy and adverse events data from the Neo-Red-P phase I trial in Prostate cancer presented at CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference(CICON-2024)
  • 02 May 2024 Bristol-Myers Squibb terminates a phase I/II trial in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Belgium, Canada, Israel, Finland, Netherlands, Norway, Poland, Spain, Germany, Italy, Argentina, Chile, France, Romania, Switzerland, Finland (IV) due to change in business objectives (NCT03110107) (EudraCT2017-000597-11)
  • 05 Apr 2024 Efficacy and adverse events data from the Neo-Red-P phase I trial in Prostate cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top